ONCrg Sentinel – Oncology Resource Group

Proficient + Discerning = Best-In-Class

Since our CI experts are highly proficient in conducting surveillance and are already on the cutting-edge of knowledge in their cancer areas, they can run extensive searches and are adept at discerning what new scientific, clinical and market events impact their landscapes and can provide intelligent insight to clients about the future marketplace.

Our analysts vigilantly monitor multiple secondary and primary sources to comprehensively cover clinical trials, product developments, company activities, and regulatory news to deliver monthly reports with unparalleled CI value.

ONCrg Sentinel™TrialsProductsCompaniesRegulatory

ONCrg Sentinel:

ONCrg specialists vigilantly monitor scientific, clinical and commercial developments via multiple secondary and primary sources to provide expert CI support year-round with succinct but comprehensive analyses of market changes and new data releases.

Trials:

Our comprehensive coverage of clinical trials include a brief write up about estimated completion date changes, significant enrollment changes, and clinical trials on hold or terminated and why. More detailed analysis and insights are provided for new and completed clinical trials Ph II and greater.

Products:

We look for information that is scientifically and clinically relevant to our pipelines (all drugs in Phase II development and beyond), whether it is regulatory news, product news, company news, or clinical trial news.

Companies:

Our analysis of company news includes coverage of research, development and marketing collaborations, alliances, mergers, acquisitions, IPOs and major funding activities, and other major commercial developments in oncology.

Regulatory:

Our analysis of regulatory news includes coverage of FDA approvals, breakthrough therapy designations, Orphan Drug designations, BLA submissions, as well as European Commission, NICE and other major regional activities.

Our best-in-class competitive intelligence coverage serves commercial, medical and scientific teams worldwide.

Solid Tumors
GI - Gastrointestinal	GU - Genitourinary	Breast / Gyn	Lung	Other
Colorectal	Bladder	Breast	NSCLC	Gliomas
Esophageal	Prostate	Endometrial	SCLC	HNSCC
Gastric	RCC	Ovarian		Melanoma
HCC				STS
Pancreatic

Immuno-Oncology	MOAs	Hematologic Malignancies
Emerging IO	ADC	ALL	MDS	MPNs
Late Stage IO	Cell Therapies	AML	MM	NHL
	DDR	CLL

Our best-in-class competitive intelligence coverage serves commercial, medical and scientific teams worldwide.

Solid Tumors

GI - Gastrointestinal

Colorectal Esophageal Gastric HCC Pancreatic

GU - Genitourinary

Bladder Prostate RCC

Breast / Gyn

Breast Endometrial Ovarian

Lung

NSCLC SCLC

Other

Gliomas HNSCC Melanoma STS

Immuno-Oncology

IO Emerging IO Late Stage

MOAs

ADC Cell Therapies DDR

Hematologic Malignancies

ALL AML CLL MDS MM MPNs NHL

Why We Make a Difference

Oncology Coverage

“My team here loves the work ONCrg does – we are constantly pulling these reports up for various reasons and they are so AWESOME! Thanks so much!”

“Wow, very helpful and nice. I appreciate the preview of coming attractions! Thank you very much, helps my story a lot with this unbiased view of the market…”

“I have to say, this is one of the best intelligence services I have ever used. You and your team do a great job”

“What I value most from ONCrg is the unfiltered unbiased view you give irrespective of what manufacturers say. We love the key implications you put together and why they matter”

“As always you guys hit these reports out of the park!! These are so great…. for the first time I’m not making data slides post conferences so thank you for that!”

“ I really liked your past, present and future perspectives. This is some of the best work I have ever seen from a vendor.”

“BRAVO!! Most comprehensive map that I have reviewed for current SOC; and then every MoA and compound in development. Very Impressive. My hat is tipped to your team. I will distribute it across to my team and School is in Session.”

“Our organization is extremely frugal so we always have budget challenges but your value us extremely good and we love working with you so we absolutely want to continue investing in ONCrg.”

“These reports are incredibly informative and helpful as we think about our research strategy and drug developments options in these indications. I greatly appreciate you and the ONCrg team’s efforts to generate these reports and summaries.

“This is great! Until you’ve tried to attend a conference and make sense of what you saw and heard there, you can’t appreciate how hard it is to do it, so this is a really nice way of distilling the information.”

“I have been supporting myeloma brand for 3 years. This level of quality is what I am personally looking for and beyond what typical CI vendors can do….I see you have subject matter experts in each therapeutic area.”

“ONCrg has really good data and really good analysts, which was not what I found at Big Pharma or Small Pharma”

“I really appreciate working with you and the great support you have provided over the last couple of years! The internal feedback was quite positive: Very clear and precise statements; nice format – holistic and comprehensive”

“This is an outstanding summary of ASCO GU! We really appreciate all the detailed summaries and implications provided in this report. The clear insights your team provide continue to be fantastic! We use your upfront slides to convey complicated information to senior leadership.”

“Wow! This is amazing. Literally exactly what I was looking for. Thanks so much!! You’re the best.”

“This fully answers my question. This additional information and timely response is also extremely helpful in filling some of the gaps I had as I prepare for upcoming governance meetings.”

“My organization relies so heavily on ONCrg. I’m one of the strongest advocates and will continue to be, not just for conferences but across the board. “Our senior managers absolutely love the competitive landscape diagrams in your Pipeline Strategies reports.”

“I love the tumor specific reports that give me a lay of the land, are easily digestible. I really appreciate the implications and commentary in each report.”

“I know that many really like what you’re doing…everyone was thankful and found the reports very helpful”

I have always found the ONCrg reports to be valuable and to have evolved in sync with the changing times in oncology (not all vendors have).”

“The fact that ONCrg got our vaccine right is proof that we have done our research”. Also, there were 3 things I picked up from your vaccine presentation that I didn’t know. Quite helpful.”

“The way you do implications was exactly how I would like them to be delivered from a company covering them at ESMO”

“Thank you so much for the Onc-rg reports that your team provides. These reports are very helpful to the field medical team!”

“Thanks team, this is making my life easier already”

“I am quite impressed with the approach that you have taken to developing market assessments based on clinical trials reporting in a variety of settings. I appreciate the access to the meeting trials compendia in my core areas of interest”

“Thank you for the excellent work that you have delivered and for the wonderful partnership we have enjoyed.”

“I find the depth of information and their very succinct explanations to be extremely well written and easy to read, so this would enable me to stay aware of compounds moving up the ladder. Great work”

“I assume you have many clients, so I really appreciate how you can customize the coverage to our needs, I don’t know how you do it.”

“Take the opportunity to check out the “Implications” box on each slide. This agency is excellent at providing valuable context for new data. We will get these reports once a month as well as some really helpful supplementary reports.”

“Thanks for the support and fantastic customer service.”

“Thanks for all the ASCO updates in RCC, breast, IO, etc. They really are terrific and help tremendously with our MA debrief…”

Why We Make a Difference

Oncology Coverage

Footer